Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Schizophrenia

Schizophrenia

Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those diagnosed.

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...

Psychological and Sociocultural Causes of Schizophrenia

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms.

Schizophrenia bulletin open·2026

Same author

Biological insights into schizophrenia from ancestrally diverse populations.

Nature·2026

Same author

Latent class analysis of symptoms across schizophrenia, schizoaffective disorder, and bipolar I disorder.

medRxiv : the preprint server for health sciences·2025

Same author

Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia.

Neuropsychiatric disease and treatment·2025

Same author

Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia.

Expert opinion on drug metabolism & toxicology·2025

Same author

Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia.

Neuropsychiatric disease and treatment·2025

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Understanding and treating "first-episode" schizophrenia.

Peter J Weiden¹, Peter F Buckley, Michael Grody

¹Department of Psychiatry, University of Illinois Medical Center, Chicago, IL, USA. pweiden@psych.uic.edu <pweiden@psych.uic.edu>

The Psychiatric Clinics of North America

|August 28, 2007

Summary

Early intervention for first-episode schizophrenia is crucial for long-term outcomes. Optimal management during this critical phase can positively impact the illness trajectory for individuals with schizophrenia.

More Related Videos

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

Related Experiment Videos

Last Updated: Jul 12, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

Area of Science:

Psychiatry
Neuroscience
Clinical Psychology

Background:

First-episode schizophrenia presents unique challenges in clinical and research settings.
The traditional view of schizophrenia as a deteriorating illness is being revised.
Understanding pre-episode factors and environmental risks like adolescent marijuana use is evolving.

Purpose of the Study:

To emphasize the critical importance of the first episode of schizophrenia.
To highlight the potential for early intervention to influence long-term outcomes.
To inform clinicians about effective management strategies for this patient population.

Main Methods:

Review of current clinical and research understanding of early schizophrenia.
Analysis of evidence-based approaches for managing first-episode psychosis.
Focus on pharmacologic response, side effect sensitivity, and medication adherence.

Main Results:

Early management can favorably influence the long-term trajectory of schizophrenia.
Certain interventions are more effective, requiring understanding of patient/family experiences.
Antipsychotic therapy should aim for broad response while monitoring for side effects and discontinuation risk.

Conclusions:

Identifying and intervening early in schizophrenia is vital.
Proactive management of side effects and adherence is essential.
Optimizing initial treatment can improve long-term prognosis for individuals with first-episode schizophrenia.